Related Experiment Video
Updated: Apr 28, 2026
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities
Elena López Villar1, Duojiao Wu, William C Cho
1Hospital Universitario Infantil Niño Jesús, Madrid, Spain.
Insights
Proteomics research offers new hope for treating paediatric acute lymphoblastic leukaemia (ALL). This study highlights the need for biomarkers to monitor treatment effectiveness and predict outcomes in children with ALL.
Area of Science:
- Biochemistry
- Oncology
- Proteomics
Background:
- Significant advancements in paediatric acute lymphoblastic leukaemia (ALL) treatment since 1950 have improved overall prognosis.
- Despite progress, there is a critical need for disease-specific biomarkers to monitor therapeutic efficacy and predict patient outcomes in paediatric ALL.
- Current research focuses on identifying protein biomarkers for drug resistance or sensitivity within signalling networks.
Purpose of the Study:
- To overview proteomics-based research in paediatric ALL.
- To discuss advances in combating cancer cells and identifying novel protein biomarkers.
- To highlight the significance of phospho-quantitative strategies for paediatric ALL in relapse and remission phases.
Main Methods:
- Overview of proteomics-based research in paediatric ALL.
- Analysis of human body fluids (cerebrospinal, peripheral blood, bone-marrow).
- Assessment of analytical schedules for body fluids from patients in different disease states.
Main Results:
- Proteomics offers a powerful approach to discover ALL-specific and sensitive biomarkers.
- Phospho-quantitative strategies are crucial for distinguishing between relapse and remission in paediatric ALL.
- The study emphasizes the potential of proteomics to map signalling networks in leukaemic cells.
Conclusions:
- Proteomics-based research is vital for advancing paediatric ALL treatment.
- Identifying reliable biomarkers can significantly improve patient monitoring and prognosis prediction.
- Further research using proteomics can lead to better therapeutic strategies for relapsed ALL.
Abstract:
There are important breakthroughs in the treatment of paediatric acute lymphoblastic leukaemia (ALL) since 1950, by which the prognosis of the child majority suffered from ALL has been improved. However, there are urgent needs to have disease-specific biomarkers to monitor the therapeutic efficacy and predict the patient prognosis. The present study overviewed proteomics-based research on paediatric ALL to discuss important advances to combat cancer cells and search novel and real protein biomarkers of resistance or sensitivity to drugs which target the signalling networks. We highlighted the importance and significance of a proper phospho-quantitative design and strategy for paediatric ALL between relapse and remission, when human body fluids from cerebrospinal, peripheral blood, or bone-marrow were applied. The present article also assessed the schedule for the analysis of body fluids from patients at different states, importance of proteomics-based tools to discover ALL-specific and sensitive biomarkers, to stimulate paediatric ALL research via proteomics to 'build' the reference map of the signalling networks from leukemic cells at relapse, and to monitor significant clinical therapies for ALL-relapse.
